Wall Street falls as trade hopes wane
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Apple (AAPL) Opens Lower as Tech Pressured, Down 2.75%
December 3, 2019 9:31 AM ESTApple (NASDAQ: AAPL) Opens Lower as Tech Pressured, Down 2.75%
... MoreH.C. Wainwright Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition
December 3, 2019 7:15 AM ESTH.C. Wainwright analyst Debjit Chattopadhyay downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreMizuho Securities Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition
December 3, 2019 6:53 AM ESTMizuho Securities analyst Difei Yang downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral with a price target of $60.00.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... More